

Maryland Medicaid Office of Pharmacy Services

Tel: 1-855-283-0876 Fax: 1-833-485-2524 Alt Fax: 1-410-618-4168

Request to Authorize Long-Acting Antipsychotic Injection (LAI) Prescription for Youth 17 and Younger Incomplete forms will be returned

Patient Information										
Patient Name:				DOB (mm/dd/yyyy):						
Last	name	First name	MI	Height (inches):	Date:					
Maryland Medicaid #:										
☐ Male ☐ Female				weight (pounds):	Date:					
Prescriber Information										
				NPI #:						
Lo	ast name	First name	МІ	Tel:						
Treatment site or o	ffice address:			Treatment site or office fax:						
Medical Specialty:				Email address:						
Contact person for	Contact person for this request:									
Prescriber Information										
Purpose of Request: ☐ Start an LAI ☐ Continue an LAI that the patient is currently receiving										
Which LAI do you wish to prescribe at what dose?										
I plan to: Continue oral antipsychotics with LAI Continue oral antipsychotic for days Discontinue oral antipsychotic after LAI administered The patient is not currently receiving an oral antipsychotic										
The Maryland Medicaid Preferred Drug List is located at: https://health.maryland.gov/mmcp/pap/pages/preferred-drug-list.aspx Antipsychotics are listed under the category Central Nervous System.										
Last injection:	Date:	Drug:	Dose adm	Dose administered:						
	Administered by: Facility:									
		Schedule	for next three injection	ns						
Date	Date Planned Dose			To be administered by/Facility						
Antipsychotic		Current Strength	Antipsychotic Regimen	Regimen	Total Daily Dose					
,,		2.1.0.1811								
☐ This is a continuation of inpatient or emergency treatment. If so, date of initiation of antipsychotic:										

CONTINUED ON NEXT PAGE

☐ There is a plan to discontinue or taper an antipsychotic in this patient (specify antipsychotic): ____

Patient Name: _						
		DSM Diagnosi	S (please check all that appl	lv)		
☐ Attention-Deficit☐ Autism Spectrum	:/Hyperactivity Disorde	r (ADHD) 🗆 Obsessive Co	mpulsive Disorder Defiant Disorder	☐ Schizoph	nrenia nreniform Disorder	
☐ Bipolar Disorder		• • • • • • • • • • • • • • • • • • • •	☐ Panic Disorder		☐ Substance Use Disorder	
☐ Conduct Disorder ☐ Psychotic Disorder (other)				☐ Tourette	•	
•	Dysregulation Disorde			☐ Traumat	ic Brain Injury	
☐ Generalized Anxi☐ Intellectual Disable	•		tic Stress Disorder Ichment Disorder	☐ Other Di	cordor	
☐ Major Depressive	•	□ Schizoaffective		Specify		
□ Aggression	□ Hallusinations		ns (please check all that ap		and a company to the control of the	
☐ Aggression☐ Anxiety	☐ Hallucinations☐ Hyperactivity	☐ Mania☐ Mood Instability		i ne check at risk of:	ed symptoms place the child	
☐ Assault	☐ Impulsivity	☐ Self-injurious behavior		☐ Hospitalization		
☐ Delusions	☐ Insomnia	☐ Other Symptoms (specify	v):	☐ Out of home placement		
□ Depression	☐ Irritability	ability		\square Suspension/expulsion from school		
				☐ Danger t		
				☐ Danger t	o others	
			alues and Rating Scales	S		
Fasting Glucose:		Fasting Lipids:	Hepatic Function:	<u>Abnor</u>	mal Involuntary Movement	
Date:		Date:	Date:	<u>Scale:</u>		
Value:		Triglycerides:	AST:		 	
		LDL:	ALT:	Score:		
		HDL:				
Please provide an	explanation for any	missing laboratory informat	ion:			
	INON	Pharmacologic Treat	ment and Other Clinica	ii information		
The patient is cur	rently receiving non	-pharmacologic/psychosocia	l services (may include school b	pased services).		
□yes □no □refe	erred and appointme	ent pending				
•						
Please specify the	e type of non-pharm	acologic/psychosocial service	es:			
The patient has a	known history of ab	ouse or trauma. 🗆 yes 🗆 no				
	Oth	er Psychopharmacolo	ogic Agents the Patient	is Receiving		
Medicati		Strength/Frequency			Indication	
			_			
		Provious	Antipsychotic Trials			
20 11 11						
Medicati	on	Strength/Frequency	Approximate Dates of	Trial	Indication	
		Continuation	of Care and Certificatio	n		
It is likely that this	s nationt will he tran	sferred to the care of anoth	er provider			
it is likely that this	s patient win be trai	isierieu to the care of anothi	er provider. 🗆 yes 🗀 no			
If yes, to whom?						
Loortify that the h	annafita of antinovah	atic tractment for this nation	at auturaigh the risks and verify	, that the information	a arayidad an this form is	
			nt outweigh the risks and verify			
	· · · · · · · · · · · · · · · · · · ·	-	scriber acknowledge and agree			
signature, which	shall be considered a	as an original signature for al	I purposes and shall have the sa	ame force and effect	as original signature.	
Prescriber Signati	ure:			Date:		